Shuttle Pharmaceuticals (NASDAQ:SHPH) Shares Up 0.6% – Still a Buy?

Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) traded up 0.6% during mid-day trading on Tuesday . The company traded as high as $0.60 and last traded at $0.5860. 102,202 shares traded hands during trading, a decline of 96% from the average session volume of 2,359,710 shares. The stock had previously closed at $0.5823.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings lowered Shuttle Pharmaceuticals from a “sell (e+)” rating to a “sell (e)” rating in a report on Monday, May 18th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock currently has a consensus rating of “Sell”.

Shuttle Pharmaceuticals Stock Up 0.6%

The stock has a fifty day moving average of $0.81 and a 200-day moving average of $1.34. The stock has a market cap of $3.43 million, a PE ratio of -0.12 and a beta of 0.38.

Shuttle Pharmaceuticals (NASDAQ:SHPH) last released its quarterly earnings results on Friday, May 15th. The company reported ($0.43) earnings per share (EPS) for the quarter.

Institutional Investors Weigh In On Shuttle Pharmaceuticals

Hedge funds have recently added to or reduced their stakes in the company. Geode Capital Management LLC acquired a new stake in Shuttle Pharmaceuticals in the fourth quarter valued at about $26,000. Boothbay Fund Management LLC acquired a new stake in Shuttle Pharmaceuticals in the fourth quarter valued at about $37,000. Ikarian Capital LLC acquired a new stake in Shuttle Pharmaceuticals in the fourth quarter valued at about $124,000. Finally, Connective Capital Management LLC acquired a new stake in Shuttle Pharmaceuticals in the third quarter valued at about $357,000. Institutional investors and hedge funds own 4.58% of the company’s stock.

About Shuttle Pharmaceuticals

Shuttle Pharmaceuticals Holdings, Inc, a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers .